Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.87 USD
+0.25 (2.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.87 USD
+0.25 (2.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
by Zacks Equity Research
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.
Iovance (IOVA) Down After Announcing Data From Melanoma Study
by Zacks Equity Research
Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
by Zacks Equity Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.
Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August
by Zacks Equity Research
Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.
Iovance (IOVA) to Start Clinical Studies for TIL Therapy
by Zacks Equity Research
Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.
Iovance Biotherapeutics (IOVA) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) has been struggling lately, but the selling pressure may be coming to an end soon.
Wall Street Analysts Think Iovance Biotherapeutics (IOVA) Could Surge 52%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Iovance Biotherapeutics (IOVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 49% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 49% upside potential for Iovance Biotherapeutics (IOVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
by Zacks Equity Research
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
Implied Volatility Surging for Iovance (IOVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Iovance (IOVA) stock based on the movements in the options market lately.
Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
by Zacks Equity Research
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
by Zacks Equity Research
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
Is the Options Market Predicting a Spike in Iovance Biotherapeutics (IOVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.
Why Is Iovance Biotherapeutics (IOVA) Down 21.5% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.
Why Is Iovance Biotherapeutics (IOVA) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
Iovance Stock Down on Delay in Filing for Melanoma Candidate
by Zacks Equity Research
Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.